Sierra Oncology, Inc. (SRRA): Price and Financial Metrics

Sierra Oncology, Inc. (SRRA): $54.99

0.02 (+0.04%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Add SRRA to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#211 of 400

in industry

SRRA Price/Volume Stats

Current price $54.99 52-week high $55.19
Prev. close $54.97 52-week low $14.91
Day low $54.98 Volume 862,800
Day high $55.17 Avg. volume 931,731
50-day MA $54.73 Dividend yield N/A
200-day MA $33.52 Market Cap 1.34B

SRRA Stock Price Chart Interactive Chart >


Sierra Oncology, Inc. (SRRA) Company Bio


Sierra Oncology, Inc., formerly known as ProNAi Therapeutics, is a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform. The company was founded in 2003 and is based in Vancouver, Canada.


SRRA Latest News Stream


Event/Time News Detail
Loading, please wait...

SRRA Latest Social Stream


Loading social stream, please wait...

View Full SRRA Social Stream

Latest SRRA News From Around the Web

Below are the latest news stories about Sierra Oncology Inc that investors may wish to consider to help them evaluate SRRA as an investment opportunity.

Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SAN MATEO, Calif., February 18, 2022--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, granted a stock option to one new employee as approved by the Compensation Committee of the Company’s Board of Directors, under Sierra Oncology’s 2018 Equity Inducement Plan. The 2018 Equity Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such in

Yahoo | February 18, 2022

Harley-Davidson, SOC Telemed Stocks See Action From Activist Investors

H Partners raised its investment in motorcycle giant Harley-Davidson. Warburg PIncus has a large stake in telemedecine firm SOC Telemed.

Yahoo | February 12, 2022

Sierra Oncology raises additional funds from underwriters of stock offering

Sierra Oncology (NASDAQ:SRRA) said the underwriters of its previously announced public offering exercised in full their option to buy an additional 750K common shares at $27 per share. With this exercise, the gross proceeds to Sierra were ~$155.3M. Sierra intends to use the net proceeds to prepare for potential commercialization of...

Seeking Alpha | February 3, 2022

Sierra Oncology Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN MATEO, Calif., February 03, 2022--Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced that the underwriters of its previously announced underwritten public offering exercised in full their option to purchase 750,000 additional shares of common stock at a price of $27.00 per share, before deducting underwriting discounts and commissions. With this exercise, the aggregate gross proceeds to Sie

Yahoo | February 3, 2022

Sierra Oncology to Participate in Guggenheim Oncology Conference

SAN MATEO, Calif., February 03, 2022--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the company will participate in the 4th Annual Guggenheim Oncology Conference being held virtually from February 9 – 11, 2022. President and Chief Executive Officer Stephen Dilly, MBBS, PhD, will participate in an analyst-moderated fireside chat on Thursday, February 10, 2022, at 12:00 pm ET.

Yahoo | February 3, 2022

Read More 'SRRA' Stories Here

SRRA Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year 219.90%
5-year -19.61%
YTD N/A
2023 N/A
2022 0.00%
2021 35.62%
2020 17.04%
2019 -74.06%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!